28 July 2026 in Pharmaceutical Science and Technology
Balanites aegyptiaca (L.) Del. is a plant whose fruit pulp is traditionally used to treat constipation. They possess inherent laxative properties. This study aimed to improve upon the traditional method of use by developing lozenges with these laxative properties. An infusion was performed, and the physicochemical characteristics of the lyophilized extract were determined. The lozenges were formulated from the extract, and their quality and laxative efficacy in vivo were controlled in NMRI strain mice. The extract was yellow, had a bitter-sweet taste, a characteristic smell, and a fine texture. The pH was 5.56, and the RMC was 1.16%. The powder was highly hygroscopic, and the extraction yield was 33.71%, with a saponoside content of 2.76 μgED/mg. Fifteen (15) formulations were prepared, and formulation F7 was selected for the incorporation of the extract. The F7 was yellow, sweet, with an uncharacteristic odor and a hard appearance. The lozenges were uniform (1.95±0.04 g), with an average pH of 5.85±0.07 and a saponoside content of 2.01±0.26 μgED/mg. The lozenges had an accelerated intestinal transit percentage of 75.74±3.22%, comparable to that of the extract (78.10±4.32%) and castor oil (81.84±9.46%). After slowing down transit with loperamide (45.24±2.38%), the lozenges (60.84±7.13%) brought the percentage close to normal transit (65.94±3.33%). This study highlighted the laxative efficacy of lozenges made from Balanites aegyptiaca fruit pulp extract.
20 February 2025 in Pharmaceutical Science and Technology
Introduction: Sickle cell disease is a genetic disease that affects nearly 5% of the world's population and is particularly prevalent in sub-Saharan Africa. The inaccessibility of modern treatment has led to the development of a phytomedicine called FACA® in Burkina Faso. It is formulated in capsule form and contains a mixture of powdered root barks of Zanthoxylum zanthoxyloides and Calotropis procera . This study aims to propose an alternative, easier-to-administer form for patients who have difficulty swallowing capsules by developing effervescent granules. Materials and methods: Pre-formulation studies focused on analyzing the physicochemical and pharmaco-technical properties of the powder mixture. These included macroscopic and organoleptic aspects, pH, residual moisture content, hygroscopicity, granulometry, and flow. Effervescent granules were formulated and manufactured by the wet granulation method. Five formulations (F1-F5) were produced. Citric acid and sodium bicarbonate were used as effervescent vehicles at a ratio of 1:1.25. PVP was used as a binding agent, sucrose as a sweetener, and cornstarch as a diluent. The granulation liquid was distilled water. The granules produced were evaluated for their physicochemical properties and disintegration time. Results and discussion: the results of the physicochemical and pharmaco-technical characteristics guided the choice of excipients and the manufacturing process. The formulations were beige in color and granular in appearance. THR values were <10%, pH ranged from 5.20 ± 0.29 to 5.91 ± 0.17. They were more or less hygroscopic and presented good rheological properties with an effervescence time satisfying the specifications of the European Pharmacopoeia 11th edition. Conclusion: F4 formulation had the best characteristics and could serve as an alternative to capsules. Indeed, being dispersed in water before administration, these granules could be well tolerated by the gastrointestinal tract and promote a more rapid action of the drug at a time of crisis.